A Study of LY2216684 in Healthy Participants

NCT01380691 | Completed Phase 1 Results

• 2 other identifiers: 12613H9P-EW-LNCV
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 1

Brief Summary

This study will evaluate the pharmacodynamic and pharmacokinetic interaction of LY2216684 with alcohol in healthy participants. This study will run approximately for 34 days.

Conditions

Major Depressive Disorder

Outcome Measures

Primary Outcomes (4)

• Change From Baseline to 10 Hours in Power of Attention Composite Score

  Power of attention is a measure of focused attention and information processing speed; based on the summed reaction times from the simple reaction time, choice reaction time, and digit vigilance tasks. Scores are measured by response latencies, and smaller scores indicate better function. Least squares (LS) means were calculated using mixed model analysis of covariance (ANCOVA) adjusting for predose, sequence, period, day, time, treatment, and treatment\*time as fixed effects and participant within sequence and treatment as random effect.

  Baseline, 10 hours

• Change From Baseline to 10 Hours in Continuity of Attention Composite Score

  Continuity of attention is a measure of sustained attention, combining (summed) accuracy and error measures from the choice reaction time and digit vigilance tasks. The number of correct responses (out of 50) for choice reaction time was added to the total number of targets correctly identified (out of 45) digit vigilance minus the number of false alarms (total score of -45 to 95). A high score reflects someone able to keep his/her mind on a single task for a prolonged period. A negative change from baseline reflects impairment compared to baseline. LS means were calculated using mixed model ANCOVA adjusting for predose, sequence, period, day, time, treatment, and treatment\*time as fixed effects and participant within sequence and treatment as random effect.

  Baseline, 10 hours

• Change From Baseline to 10 Hours in Postural Stability

  The ability to stand upright without moving was assessed using equipment modeled on the Wright Ataxia-meter. To measure movements, a cord was attached to the participant who was required to stand for one minute, as still as possible, with feet apart and eyes closed. The amount of sway is expressed as the total angular movement calibrated in units of one-third degree of angle of sway. The amount of sway is expressed as the total angular movement in the antero-posterior plane and calibrated in units of one-third degree of angle of sway. Higher result indicates better postural stability. A negative change from baseline reflects impairment compared to baseline. LS means were calculated using mixed model ANCOVA adjusting for predose, sequence, period, day, time, treatment, and treatment\*time as fixed effects and participant within sequence and treatment as random effect.

  Baseline, 10 hours

• Change From Baseline to 10 Hours in Self-Rated Alertness

  Assessed via the Bond and Lader Visual Analogue Scale (VAS), which utilizes a 16-point scale of 0 to 100 with 0 representing the worst rating and 100 representing the best rating. LS means were calculated using mixed model ANCOVA adjusting for predose, sequence, period, day, time, treatment, and treatment\*time as fixed effects and participant within sequence and treatment as random effect.

  Baseline, 10 hours

Secondary Outcomes (10)

• Pharmacokinetics: Observed Maximum Plasma Concentration (Cmax) of LY2216684

  Predose through 24 hours postdose

• Pharmacokinetics: Observed Cmax of Alcohol

  Predose through 24 hours postdose

• Pharmacokinetics: Observed Time to Maximum Plasma Concentration (Tmax) of LY2216684

  Predose through 24 hours postdose

• Pharmacokinetics: Observed Tmax of Alcohol

  Predose through 24 hours postdose

• Pharmacokinetics: Area Under the Concentration Time Curve Over a Dosing Interval (AUCt) of LY2216684

  Predose through 24 hours postdose

Study Arms (4)

LY, Alc, Pl-Match Alc, Then Pl-Match LY, Alc, Pl-Match Alc

EXPERIMENTAL

Period 1: 18 milligrams (mg) LY2216684 (LY) administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic (Alc) beverage (with an alcohol dose of 0.6 grams per kilograms \[g/kg\] for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching (Pl-Match) alcoholic beverage, taken orally, one time. Period 2: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. There was a 7-day washout period between Periods 1 and 2.

Drug: LY2216684; Drug: Placebo-matching LY2216684; Drug: Placebo-matching alcoholic beverage; Drug: Alcoholic beverage

Pl-Match LY, Alc, Pl-Match Alc, Then LY, Alc, Pl-Match Alc

EXPERIMENTAL

Period 1: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. Period 2: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. There was a 7-day washout period between Periods 1 and 2.

Drug: LY2216684; Drug: Placebo-matching LY2216684; Drug: Placebo-matching alcoholic beverage; Drug: Alcoholic beverage

LY, Pl-Match Alc, Alc, Then Pl-Match LY, Pl-Match Alc, Alc

EXPERIMENTAL

Period 1: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. Period 2: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. There was a 7-day washout period between Periods 1 and 2.

Drug: LY2216684; Drug: Placebo-matching LY2216684; Drug: Placebo-matching alcoholic beverage; Drug: Alcoholic beverage

Pl-Match LY, Pl-Match Alc, Alc, Then LY, Pl-Match Alc, Alc

EXPERIMENTAL

Period 1: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. Period 2: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. There was a 7-day washout period between Periods 1 and 2.

Drug: LY2216684; Drug: Placebo-matching LY2216684; Drug: Placebo-matching alcoholic beverage; Drug: Alcoholic beverage

Interventions

LY2216684 DRUG

Administered orally

Also known as: Edivoxetine

LY, Alc, Pl-Match Alc, Then Pl-Match LY, Alc, Pl-Match Alc; LY, Pl-Match Alc, Alc, Then Pl-Match LY, Pl-Match Alc, Alc; Pl-Match LY, Alc, Pl-Match Alc, Then LY, Alc, Pl-Match Alc; Pl-Match LY, Pl-Match Alc, Alc, Then LY, Pl-Match Alc, Alc

Placebo-matching LY2216684 DRUG

Administered orally

LY, Alc, Pl-Match Alc, Then Pl-Match LY, Alc, Pl-Match Alc; LY, Pl-Match Alc, Alc, Then Pl-Match LY, Pl-Match Alc, Alc; Pl-Match LY, Alc, Pl-Match Alc, Then LY, Alc, Pl-Match Alc; Pl-Match LY, Pl-Match Alc, Alc, Then LY, Pl-Match Alc, Alc

Placebo-matching alcoholic beverage DRUG

Administered orally

LY, Alc, Pl-Match Alc, Then Pl-Match LY, Alc, Pl-Match Alc; LY, Pl-Match Alc, Alc, Then Pl-Match LY, Pl-Match Alc, Alc; Pl-Match LY, Alc, Pl-Match Alc, Then LY, Alc, Pl-Match Alc; Pl-Match LY, Pl-Match Alc, Alc, Then LY, Pl-Match Alc, Alc

Alcoholic beverage DRUG

Administered orally

LY, Alc, Pl-Match Alc, Then Pl-Match LY, Alc, Pl-Match Alc; LY, Pl-Match Alc, Alc, Then Pl-Match LY, Pl-Match Alc, Alc; Pl-Match LY, Alc, Pl-Match Alc, Then LY, Alc, Pl-Match Alc; Pl-Match LY, Pl-Match Alc, Alc, Then LY, Pl-Match Alc, Alc

Eligibility Criteria

• Age: 21 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Overtly healthy male or female participants, as determined by medical history and physical examination
• Male participants: Agree to use a reliable method of birth control during the study and for 1 month following the last dose of study drug
• Female participants: Women of child-bearing potential who test negative for pregnancy at the time of enrollment, have used a reliable method of birth control for 6 weeks prior to administration of study drug, and agree to use a reliable method of birth control during the study and for 1 month following the last dose of study drug (hormonal methods of contraception, including oral and implantable contraceptives, are not allowed in this study) or women who are not of child-bearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or due to menopause (at least 1 year without menses or 6 months without menses and a follicle stimulating hormone \[FSH\] \>40 milli-international units/milliliter \[mIU/mL\])
• Male and female participants: Examples of reliable methods of birth control include double-barrier methods (for example, condom and spermicide) alone or in combination with vasectomy, vasectomized partners, and abstinence.
• Have a body weight \>50 kilogram (kg)
• Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator
• Have venous access sufficient to allow for blood sampling
• Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
• Have given written informed consent approved by Lilly and the institutional review board (IRB) governing the site
• Have normal blood pressure and pulse rate (in sitting position) as determined by the investigator

You may not qualify if:

• Are currently enrolled in or have completed or discontinued within the last 30 days from a clinical trial involving an investigational product other than the study drug used in this study; or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
• Have known allergies to LY2216684, related compounds or any components of the formulation
• Are persons who have previously received the investigational product in this study or have completed or withdrawn from this study or any other study investigating LY2216684 within 6 months prior to Screening
• Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study.
• Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders that are capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
• Have a history or show evidence of significant active neuropsychiatric disease or have a history of suicide attempt or ideation
• Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
• Participants with a past history of alcohol dependence/abuse
• Show evidence of human immunodeficiency virus (HIV) infection and/or positive HIV antibodies
• Show evidence of hepatitis C and/or positive hepatitis C antibody
• Show evidence of hepatitis B and/or positive hepatitis B surface antigen
• Women with a positive pregnancy test or women who are lactating
• Intend to use over-the-counter or prescription medication within 14 days prior to dosing or during the study unless deemed acceptable by the investigator and Sponsor's medical monitor, except for influenza vaccinations
• Have donated blood of more than 500 milliliter (mL) within the last month
• Have an average weekly alcohol intake that exceeds 14 units per week, or are unwilling to stop alcohol consumption 48 hours prior to each study period and while resident at the Clinical Research Unit (CRU) (except as required per this protocol); (1 unit = 12 ounces \[oz\] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)

Sponsors & Collaborators

• Eli Lilly and Company: lead

Study Sites (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Evansville, Indiana, 47710, United States

Location

MeSH Terms

Conditions

Depressive Disorder, Major

Interventions

alpha-((5-fluoro-2-methoxyphenyl)methyl)-alpha-(tetrahydro-2H-pyran-4-yl)-2-morpholinemethanol; Alcoholic Beverages

Condition Hierarchy (Ancestors)

Depressive Disorder; Mood Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Beverages; Diet, Food, and Nutrition; Physiological Phenomena; Food and Beverages

Results Point of Contact

• Title: Chief Medical Officer
• Organization: Eli Lilly Company

800-545-5979

Study Officials

• Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

  Eli Lilly and Company

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 22, 2011
• First Posted: June 27, 2011
• Study Start: June 1, 2011
• Primary Completion: September 1, 2011
• Study Completion: September 1, 2011
• Last Updated: June 26, 2019
• Results First Posted: June 26, 2019

Record last verified: 2019-04

Locations

US (1)